Advertisement Of Notice Of Twenty Third Annual General Meeting, E-Voting And Book Closure Information
Advertisement of Notice of twenty Third Annual General Meeting, e-voting and Book Closure information24-07-2018
Advertisement Of Notice Of Twenty Third Annual General Meeting, E-Voting And Book Closure Information
Advertisement of Notice of twenty Third Annual General Meeting, e-voting and Book Closure informationBoard Meeting Scheduled To Be Held On August 13, 2018.
We hereby inform that the meeting of the Board of Directors of the Company will be held on Monday, August 13, 2018 to consider apart from other agenda items to approve the unaudited financial results for the quarter ended on June 30, 2018. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from August...Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Acetylcysteine InjectionZydus Cadila gets USFDA nod for high blood pressure, heart failure treatment drug
Zydus Cadila has received final approval from the US health regulator to market Spironolactone tablets, used to treat high blood pressure and heartAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Spironolactone Tablets USPZydus Cadila gets USFDA nod for arthritis drug
Zydus Cadila has received final approval from the US health regulator for Piroxicam capsules, used for the treatment of osteoarthritis and rheumatoidAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Piroxicam Capsules USPZydus Cadila gets USFDA nod to market 4 generic products
Pharma firm Zydus Cadila today said it has received final approvals from the US health regulator to market four generic products in America. The compAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives four consecutive ANDA approvals from the USFDA